Recent SILO News
- Silo Pharma Partners with AmplifyBio to Advance SPC-15 for PTSD and Anxiety • GlobeNewswire Inc. • 06/26/2024 12:50:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 06/13/2024 09:08:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/13/2024 05:19:05 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 06/11/2024 08:00:43 PM
- Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for Fibromyalgia • GlobeNewswire Inc. • 06/07/2024 12:18:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 08:52:32 PM
- Silo Pharma Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules • GlobeNewswire Inc. • 06/06/2024 08:50:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/06/2024 10:07:51 AM
- Silo Pharma Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules • GlobeNewswire Inc. • 06/05/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 08:05:28 PM
- Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and Anxiety • GlobeNewswire Inc. • 06/04/2024 12:41:00 PM
- Silo Pharma Announces Positive Results from Study for Depression Treatment, Remission, and Relapse Prevention • GlobeNewswire Inc. • 05/21/2024 12:45:00 PM
- Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in Ketamine • GlobeNewswire Inc. • 05/14/2024 12:45:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2024 08:05:59 PM
- Silo Pharma Announces Positive Results for Intranasal PTSD Treatment • GlobeNewswire Inc. • 04/23/2024 12:15:00 PM
- Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease Therapeutic • GlobeNewswire Inc. • 04/10/2024 12:11:00 PM
- Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic • GlobeNewswire Inc. • 03/20/2024 12:30:00 PM
- Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain • GlobeNewswire Inc. • 03/18/2024 11:15:00 AM
- Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD • GlobeNewswire Inc. • 02/28/2024 01:25:00 PM
- Silo Pharma’s SP-26 Ketamine Implant Demonstrates Successful Drug Delivery • GlobeNewswire Inc. • 02/14/2024 01:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 06:15:35 PM
- Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology • GlobeNewswire Inc. • 02/01/2024 03:00:00 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/25/2024 10:29:45 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/25/2024 10:27:04 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM